Symposia at 2023 Midyear!

Don’t miss the ASHP Advantage Symposia at this year’s ASHP Midyear Clinical Meeting & Exhibition, where leading experts will provide engaging, in-person and virtual educational opportunities for attendees. Seating is limited and provided on a first-come, first-served basis.

If you are not attending the Midyear Clinical Meeting & Exhibition in person, register for the live webinars below.

Featured ASHP Advantage® Symposia at the ASHP Midyear! 

Monday, Dec. 4
11:30 AM - 1:00 PM PT | 2:30 PM - 4:00 PM ET

Cardiometabolic CareChallenges in Cardiometabolic Care: Interprofessional Implementation of SGLT2 Inhibitors

This educational activity will review the latest data from the landmark clinical trials examining the effects of SGLT2 inhibitors on cardiorenal outcomes and describe the role pharmacists can play in care models for initiation, titration, and monitoring of SGLT2 inhibitor therapy for patients who could benefit from treatment.

Guidance for the Safe Use of Parenteral Nutrition in Adult and Pediatric PatientsOptimizing Patient Safety: Guidance for the Safe Use of Parenteral Nutrition in Adult and Pediatric Patients

This educational activity will review strategies for ensuring safe and effective therapy for adult and pediatric patients when parenteral nutrition (PN) components are in short supply, review current and upcoming guidelines that relate to optimizing PN therapy, and review lipid injectable emulsion (ILE) dosing.

Optimizing PARP Inhibitor Outcomes in Cancer TherapyOptimizing PARP Inhibitor Outcomes in Cancer Therapy: Focus on Biomarkers of Homologous Recombination Repair

This interprofessional educational activity will review the science of homologous recombination deficiency and how it contributes to the development of cancer. Approved and expanded indications for the PARP inhibitors will be explained, including evidence for their use based on biomarkers, efficacy, and safety data.

Tuesday, Dec. 5
11:30 AM - 1:00 PM PT | 2:30 PM - 4:00 PM ET

Covid 19 2023COVID-19 Now and Beyond: Where Do We Go From Here?

This educational activity will provide an update on the pharmacist's role in current COVID-19 prevention and treatment including special patient populations, review new and emerging therapies, and potential implications of coverage and access to COVID-19 vaccines, therapies, and tests.

Ready-to-Administer IV Push ProductsReady-to-Administer IV Push Products: A Multidisciplinary Approach to Safety, Cost-Effectiveness, and Patient Outcomes in Health System and Perioperative Settings

This educational activity examines the landscape of considerations regarding ready-to-administer (RTA) IV push products compared with traditional IV vial products, the holistic costs of waste, and new evidence regarding perioperative opioid use and associated adverse clinical outcomes.

Contact Us